Am J Respir Crit Care Med. 2023 Jul 14. doi: 10.1164/rccm.202302-0327SO. Online ahead of print.
ABSTRACT
Major advances in pulmonary arterial hypertension (PAH), pulmonary hypertension (PH) associated with lung disease, and chronic thromboembolic PH (CTEPH) cast new light on the pathogenetic mechanisms, epidemiology, diagnostic approach, and therapeutic armamentarium for pulmonary vascular disease. Here, we summarize key basic, translational, and clinical PH reports, emphasizing findings that build the current state-of-the-art. This review includes cutting-edge progress in translational pulmonary vascular biology, a guide to the diagnosis of patients in clinical practice, incorporating recent PH definition revisions that continue emphasis on early detection of disease, and provides an overview of the evolving considerations for the management of PH patients that harbor cardiopulmonary co-morbidities as well as a discussion of the ground-breaking sotatercept data for the treatment of PAH.
PMID:37450768 | DOI:10.1164/rccm.202302-0327SO